Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARV-1004
- Development stage
- Preclinical
- Lead developer
- Pinion Immunotherapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
ARV-1004 is a preclinical-stage therapeutic mRNA vaccine being developed by Pinion Immunotherapeutics (formerly ARV Technologies) for the treatment of Epstein-Barr virus (EBV) infection. Utilizing Pinion's proprietary AI-driven mRNA platform, the candidate is formulated within engineered lipid nanoparticles (LNPs) designed to optimize lymph node trafficking, antigen-presenting cell (APC) uptake, and MHC class I loading. ARV-1004 aims to achieve durable immune control by simultaneously inducing robust CD8+ cytotoxic T lymphocyte (CTL) responses and virus-neutralizing antibodies.
Beyond the preview
Go deeper on ARV-1004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARV-1004.